Evidence map›Paper›PMID 31608435›Full record

ArticleEpilepsia2019

Ultra-long-term subcutaneous home monitoring of epilepsy-490 days of EEG from nine patients.

Sigge Weisdorf, Jonas Duun-Henriksen, Marianne J Kjeldsen, Frantz R Poulsen, Sirin W Gangstad, Troels W Kjaer

Abstract read
In one paragraph

Article in Epilepsia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Seizure Detection Devices.Journal of clinical medicine · 2025
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sigge WeisdorfDepartment of Neurology, Zealand University Hospital, Roskilde, Denmark.ORCID 0000-0001-7288-1781
Jonas Duun-HenriksenUNEEG Medical A/S, Lynge, Denmark.
Marianne J KjeldsenDepartment of Neurology, Odense University Hospital, Odense, Denmark.
Frantz R PoulsenClinical Institute, University of Southern Denmark, Odense, Denmark.
Sirin W GangstadUNEEG Medical A/S, Lynge, Denmark.
Troels W KjaerDepartment of Neurology, Zealand University Hospital, Roskilde, Denmark.ORCID 0000-0002-2105-6199

Funding

Augustinus FondenFonden til Laegevidenskabens FremmeLennart Grams Memorial FoundationThe Health Research Foundation of Region Zealand and Region of Southern DenmarkUNEEG Medical A/S
6 · The paper itself

Abstract

objectiveTo explore the feasibility of home monitoring of epilepsy patients with a novel subcutaneous electroencephalography (EEG) device, including clinical implications, safety, and compliance via the first real-life test.

methodsWe implanted a beta-version of the 24/7 EEG SubQ (UNEEG Medical A/S, Denmark) subcutaneously in nine participants with temporal lobe epilepsy. Data on seizures, adverse events, compliance in using the device, and use of antiepileptic drugs (AEDs) were collected. EEG was recorded for up to 3 months, and all EEG data were reviewed visually to identify electrographic seizures. These were descriptively compared to seizure counts and AED changes reported in diaries from the same period.

resultsFour hundred ninety days of EEG and 338 electrographic seizures were collected. Eight participants completed at least 9 weeks of home monitoring, while one cancelled participation after 4 weeks due to postimplantation soreness. In total, 13 cases of device-related adverse events were registered, none of them serious. Recordings obtained from the device covered 73% of the time, on average (range 45%-91%). Descriptively, electrographic seizure counts were substantially different from diary seizure counts. We uncovered several cases of underreporting and revealed important information on AED response. Electrographic seizure counts revealed circadian distributions of seizures not visible from seizure diaries. SIGNIFICANCE: The study shows that home monitoring for up to 3 months with a subcutaneous EEG device is feasible and well tolerated. No serious adverse device-related events were reported. An objective seizure count can be derived, which often differs substantially from self-reported seizure counts. Larger clinical trials quantifying the benefits of objective seizure counting should be a priority for future research as well as development of algorithms for automated review of data.

Indexed as

Subcutaneous TissueAdultAmbulatory CareAnticonvulsantsElectrodes, ImplantedElectroencephalographyEpilepsyFemaleHumansMaleMiddle AgedTime FactorsAnticonvulsantsEEGepilepsyhome monitoringlong-term monitoringsubcutaneous EEG

Identifiers

PMID31608435
PMCPMC6899579

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.